<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Nicola</forename><surname>Fazio</surname></persName>
							<email>nicola.fazio@ieo.it</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">European Institute of Oncology</orgName>
								<orgName type="institution" key="instit2">IRCCS</orgName>
								<address>
									<region>Milan</region>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">Roberto</forename><surname>Buzzoni</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Fondazione IRCCS Foundation</orgName>
								<orgName type="institution">The National Institute of Tumors</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><surname>Gianfranco</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Delle</forename><surname>Fave</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Hospital Sant&apos;Andrea</orgName>
								<orgName type="institution" key="instit2">La Sapienza University</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Margot</forename><forename type="middle">E</forename><surname>Tesselaar</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Netherlands Cancer Institute</orgName>
								<orgName type="institution" key="instit2">Antoni van Leeuwenhoek</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Edward</forename><surname>Wolin</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Montefiore Einstein Center for Cancer Care</orgName>
								<address>
									<settlement>Bronx</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><surname>Van Cutsem</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">University Hospitals Gasthuisberg/Leuven and KU Leuven</orgName>
								<address>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paola</forename><surname>Tomassetti</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Medical and Surgical Sciences</orgName>
								<orgName type="institution" key="instit1">S. Orsola-Malpighi Hospital</orgName>
								<orgName type="institution" key="instit2">University of Bologna</orgName>
								<address>
									<settlement>Bologna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jonathan</forename><surname>Strosberg</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Moffitt Cancer Center</orgName>
								<address>
									<settlement>Tampa</settlement>
									<region>FL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maurizio</forename><surname>Voi</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<addrLine>East Hanover</addrLine>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lida</forename><surname>Bubuteishvili-Pacaud</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Novartis Pharma AG</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Antonia</forename><surname>Ridolfi</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Novartis Pharma S.A.S</orgName>
								<address>
									<settlement>Rueil-Malmaison</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><surname>Fabian Herbst</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Novartis Pharma AG</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jiri</forename><surname>Tomasek</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">Masaryk Memorial Cancer Institute</orgName>
								<orgName type="institution" key="instit2">Masaryk University</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simron</forename><surname>Singh</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Sunnybrook Health Sciences Centre</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marianne</forename><surname>Pavel</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Charit e University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><surname>Matthew</surname></persName>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Kulke</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Dana Farber Cancer Institute</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Juan</forename><forename type="middle">W</forename><surname>Valle</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Institute of Cancer Sciences</orgName>
								<orgName type="institution" key="instit1">The Christie NHS Foundation Trust</orgName>
								<orgName type="institution" key="instit2">University of Manchester</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><surname>James</surname></persName>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Yao</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">University of Texas MD Anderson Cancer Center</orgName>
								<address>
									<settlement>Houston</settlement>
									<region>TX</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors</orgName>
								<orgName type="institution">European Institute of Oncology</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="institution">IEO</orgName>
								<address>
									<region>Milan</region>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">C64BEBC07BAF2C0207651E73B5602220</idno>
					<idno type="DOI">10.1111/cas.13427</idno>
					<note type="submission">Received: 5 July 2017 | Revised: 11 October 2017 | Accepted: 16 October 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:42+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>AC, atypical carcinoid</term>
					<term>AE, adverse event</term>
					<term>CI, confidence interval</term>
					<term>GI, gastrointestinal</term>
					<term>HR, hazard ratio</term>
					<term>NET, neuroendocrine tumor</term>
					<term>OS, overall survival</term>
					<term>PFS, progression-free survival</term>
					<term>PRRT, peptide receptor radionuclide therapy</term>
					<term>SSA, somatostatin analog</term>
					<term>TC, typical carcinoid</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>In the phase III RADIANT-4 study, everolimus improved median progressionfree survival (PFS) by 7.1 months in patients with advanced, progressive, welldifferentiated (grade 1 or grade 2), non-functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.67;</s><s>P &lt; .00001).</s><s>This exploratory analysis reports the outcomes of the subgroup of patients with lung NETs.</s><s>In RADIANT-4, patients were randomized (2:1) to everolimus 10 mg/d or placebo, both with best</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>supportive care.</s><s>This is a post hoc analysis of the lung subgroup with PFS, by central radiology review, as the primary endpoint; secondary endpoints included objective response rate and safety measures.</s><s>Ninety of the 302 patients enrolled in the study had primary lung NET (everolimus, n = 63; placebo, n = 27).</s><s>Median PFS (95% CI) by central review was 9.2 (6.8-10.9)</s><s>months in the everolimus arm vs 3.6 (1.9-5.1)</s><s>months in the placebo arm (hazard ratio, 0.50; 95% CI, 0.28-0.88).</s><s>More patients who received everolimus (58%) experienced tumor shrinkage compared with placebo (13%).</s><s>Most frequently reported (≥5% incidence) grade 3-4 drug-related adverse events (everolimus vs. placebo) included stomatitis (11% vs. 0%), hyperglycemia (10% vs. 0%), and any infections (8% vs. 0%).</s><s>In patients with advanced, progressive, well-differentiated, non-functional lung NET, treatment with everolimus was associated with a median PFS improvement of 5.6 months, with a safety profile similar to that of the overall RADIANT-4 cohort.</s><s>These results support the use of everolimus in patients with advanced, non-functional lung NET.</s><s>The trial is registered with ClinicalTrials.gov</s><s>(no.</s><s>NCT01524783).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>K E Y W O R D S</head><p><s>everolimus, lung carcinoid, neuroendocrine tumors, progression-free survival, RADIANT-4</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">| INTRODUCTION</head><p><s>Neuroendocrine tumors are a diverse group of malignancies arising from neuroendocrine cells throughout the body. <ref type="bibr" target="#b0">1</ref> The majority (&gt;90%) of NETs originating from the lungs are non-hormone secreting (i.e., non-functional). <ref type="bibr" target="#b1">2</ref> Lung carcinoids (otherwise called lung NETs) represent 22%-27% of all NETs <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref> and approximately 1%-2% of all primary lung cancers. <ref type="bibr" target="#b4">5</ref></s><s>The annual age-adjusted incidence of lung NETs increased approximately 5-fold from 1973 to 2004. <ref type="bibr" target="#b0">1</ref> Neuroendocrine neoplasms originating in the lungs are categorized into well-differentiated (low grade to intermediate grade), otherwise termed as NETs, and poorly differentiated (high grade), named neuroendocrine carcinomas.</s><s>The well-differentiated subgroup includes TC and AC, comprising 2% and 0.2% of all lung cancers, respectively. <ref type="bibr" target="#b5">6</ref></s><s>Approximately 4% of TC and 26% of AC develop distant metastases. <ref type="bibr" target="#b6">7</ref></s><s>According to an analysis of the Surveillance, Epidemiology and End Results registry, the 5-year survival rate in patients with well-differentiated lung NETs with distant metastases is 27%. <ref type="bibr" target="#b0">1</ref> Platinum and etoposide represent a relatively standard treatment in poorly differentiated lung neuroendocrine carcinoma, such as large-cell neuroendocrine carcinoma and small-cell lung cancer. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref> </s><s>7]<ref type="bibr" target="#b18">[18]</ref> However, substantial evidence regarding the efficacy of these agents as antiproliferative therapies is lacking.</s><s>Therefore, no antitumor therapy has yet been approved for patients with lung NETs.</s></p><p><s>0]<ref type="bibr" target="#b21">[21]</ref> In the phase III RADIANT-4 study, comprising of patients with advanced, progressive, well-differentiated, non-functional lung or GI NET (n = 302), everolimus showed an improvement in median PFS of 7.1 months and a 52% reduction in the risk of disease progression or death (HR, 0.48; 95% CI, 0.35-0.67;</s><s>P &lt; .00001)</s><s>compared with placebo. <ref type="bibr" target="#b22">22</ref></s><s>The present analysis aimed to further explore the efficacy and safety of everolimus in the lung subgroup of the RADIANT-4 study cohort.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">| MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">| Study design</head><p><s>RADIANT-4 was a prospective, double-blind, randomized, parallelgroup, placebo-controlled, multicenter phase III study in which everolimus 10 mg/d was compared with placebo, both with best supportive care, in patients with advanced, progressive, welldifferentiated (grade 1 or grade 2), non-functional lung or GI NET with no history of or active symptoms of carcinoid syndrome (NCT01524783).</s><s>Details of the study design were published previously. <ref type="bibr" target="#b22">22</ref></s><s>Of the 388 patients screened, 302 were randomized in a 2:1 ratio to receive everolimus or placebo.</s><s>Patients were treated until radiologically documented disease progression, intolerable toxicity, death, withdrawal of consent, or loss to follow-up.</s><s>Patients were prospectively stratified based on prior SSA therapy (yes or no), tumor origin (stratum A vs. B; based on prognostic level, stratum A [better prognosis]: appendix, cecum, jejunum, ileum, duodenum, or NET of unknown primary; stratum B [worse prognosis]: lung, stomach, rectum, and colon except cecum), and WHO performance status (0 vs. 1).</s><s>Crossover was not allowed prior to primary analyses.</s></p><p><s>If the primary analyses results indicated a statistically significant improvement in PFS, the remaining patients in the placebo arm could be provided with the option to crossover to open-label treatment with everolimus, based on the feedback from the data monitoring committee.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">| Patients</head><p><s>Adult patients (≥18 years) with pathologically confirmed, advanced (unresectable or metastatic), well-differentiated (grade 1 or grade 2 per 2010 WHO gastroenteropancreatic NET classification), <ref type="bibr" target="#b23">23,</ref><ref type="bibr" target="#b24">24</ref> nonfunctional NET of the lung or GI origin were eligible for enrollment if radiologically progressing and enrolled within 6 months from diagnosis of progression before randomization.</s><s>In addition to the treatment-na€ ıve patients, patients who discontinued previous treatments like SSA (for tumor control), interferon, or one line of chemotherapy for ≥4 weeks and PRRT for ≥6 months prior to randomization were allowed, if they had disease progression after their last treatment.</s></p><p><s>Patients with poorly differentiated or high-grade neuroendocrine carcinoma were excluded from the study.</s><s>Also, patients with pancreatic NET, or carcinoid syndrome, history of one or more lines of chemotherapy, targeted therapy, therapy with mTOR inhibitors, hepatic intra-arterial embolization within 6 months, or cryoablation or radiofrequency ablation of hepatic metastases within 2 months of randomization, or chronic treatment with corticosteroids or other immunosuppressive agents were excluded from the study.</s><s>The study was carried out in accordance with Good Clinical Practice, the ethical principles outlined in the Declaration of Helsinki, and local regulations.</s><s>An independent ethics committee or institutional review board at each participating center reviewed and approved the study and all protocol amendments.</s><s>All patients provided written informed consent.</s><s>An independent data monitoring committee provided ongoing oversight of safety and study conduct.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">| Assessment</head><p><s>All patients who underwent randomization were assessed for efficacy by cross-sectional imaging with multiphasic computed tomography or MRI every 8 weeks during the first 12 months and every 12 weeks thereafter.</s><s>Adverse events were assessed as per the NCI's CTCAE version 4.03 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4. 03_2010-06-14_QuickReference_5x7.pdf).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">| Statistical analysis</head><p><s>This is an exploratory subgroup analysis of patients with lung NET as a primary site enrolled in the RADIANT-4 study.</s><s>The full analysis set (all randomized patients) was used for all efficacy analyses.</s><s>Sample size calculations were not undertaken for the cohort of patients described in this report and so this analysis was not powered to compare the treatment groups.</s><s>Progression-free survival, by central radiology review, was analyzed using Kaplan-Meier methods.</s><s>Hazard ratios and corresponding CIs were estimated using an unstratified Cox proportional hazards model.</s><s>All patients who received on or more doses of study drug and who had one or more post-baseline safety assessments were included in the safety cohort.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">| RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">| Patient characteristics</head><p><s>Of the 302 patients in the RADIANT-4 study, 90 patients had advanced, progressive, well-differentiated, non-functional NET of lung origin and were included in this analysis; of them, 63 received everolimus and 27 received placebo.</s><s>In the everolimus arm, one patient was not treated due to withdrawal of consent.</s><s>Therefore, the safety cohort in the everolimus arm was comprised of 62 patients.</s></p><p><s>The majority of the patients were men (52.2%),</s><s>Caucasian (85.6%), and had a WHO performance status 0 (71.1%).</s><s>Prior antineoplastic therapies included SSA, chemotherapy, and radiotherapy, including PRRT.</s><s>Approximately 40% of the patients in each arm had received prior SSA for tumor control.</s><s>Among them, &gt;80% of the patients in each arm had received octreotide long-acting release (85.2% of patients in the everolimus arm vs. 81.8% of patients in the placebo arm).</s><s>The proportion of patients who had undergone surgery for primary tumor or metastatic lesions was lower in the everolimus arm (52.4%) compared with those in the placebo arm (66.7%).</s><s>The proportion of patients who had received no prior treatment was similar in the two treatment groups (14.3% vs. 11.1%).</s><s>Baseline demographics and characteristics by treatment arm are described in Table <ref type="table">1</ref>.</s></p><p><s>Either tumor morphology or grade of malignancy was collected for the lung NET patient group (n = 90).</s><s>Tumors were defined as "well" or "moderately" differentiated based on local pathology assessment.</s><s>Among the patients in whom tumor morphology was reported (n = 38), the majority were reported to have well-differentiated NET (n = 32; 84.2%).</s><s>Moderately differentiated NET was reported in 6 patients (15.8%).</s><s>Considering the lack of consensus among pathologists on the precise definition, patients with moderately differentiated NETs were eligible for inclusion in this study provided that a poorly differentiated high-grade neuroendocrine carcinoma was ruled out, consistent with the exclusion criteria of the study protocol.</s><s>Among the patients in whom tumor grade was reported (n = 51), majority (86.2%) had an intermediate grade NET.</s></p><p><s>In the patients in whom Ki-67 percentage was reported (n = 63), it varied from 0% to 60% (median, 8%).</s><s>Three patients in the everolimus arm had a Ki-67 index &gt;20% (30%, 50%, and 60%).</s><s>The investigators confirmed the eligibility of these three patients based on well-differentiated tumor morphology as reviewed by the local pathologist.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">| Treatment</head><p><s>At the data cut-off date (November 28, 2014), 47 patients (74.6%) in the everolimus arm and 24 patients (88.9%) in the placebo arm discontinued the study treatment.</s><s>Primary reasons for treatment discontinuation included disease progression (36.5% on everolimus vs. 74.1% on placebo), AEs (30.2% vs. 11.1%), and withdrawal of consent (6.3% vs. 0.0%).</s></p><p><s>The median duration of treatment was 41.8 weeks (range, 0.7-118.1 weeks) for everolimus vs 14.3 weeks (range, 4.1-91.0</s><s>weeks) for placebo.</s><s>In the everolimus arm, 43 patients (69.4%) had one or more adjustments (reduction or interruption) of everolimus dosage.</s><s>These dose adjustments were primarily attributable to AEs (69.4%).</s></p><p><s>In the placebo arm (n = 27), 8 patients (29.6%) had one or more adjustments (reduction or interruption) of dosage and 18.5% of dose adjustments were due to AEs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">| Efficacy</head><p><s>The median PFS, by central review, was 9.2 months (95% CI, 6.8-10.9)</s><s>for patients receiving everolimus compared with 3.6 months (95% CI, 1.9-5.1)</s><s>for those receiving placebo.</s><s>Everolimus improved the median PFS by 5.6 months and was associated with a 50% reduction in the risk of disease progression or death (HR, 0.50; 95% CI, 0.28-0.88)</s><s>(Figure <ref type="figure">1A</ref>).</s><s>By local investigator assessment (Fig- <ref type="figure">ure 1B</ref>), median PFS was 13.8 months (95% CI, 9.3-22.2) for patients receiving everolimus compared with 3.5 months (95% CI, 1.9-5.6)</s><s>for those receiving placebo (HR, 0.23; 95% CI, 0.13-0.41).</s><s>In addition, more patients who received everolimus (57.9%) experienced tumor shrinkage compared to those receiving placebo (13.0%).</s><s>Disease control rate in the everolimus arm was 81.0% compared with 59.3% in the placebo arm.</s><s>Everolimus improved the median PFS by approximately 5.5 months vs placebo in all the subgroups assessed, including the type of prior treatment received (Table <ref type="table">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Details of the overall response and tumor shrinkage are presented in</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">| Safety</head><p><s>The most common AEs in the lung NET subgroup, irrespective of the study drug relationship (≥20% incidence in either arm), were stomatitis (53.2% with everolimus vs. 18.5% with placebo), infections (62.9% vs. 37.0%), peripheral edema (38.7% vs. 0.0%), fatigue (37.1% vs. 29.6%),</s><s>diarrhea (37.1% vs. 7.4%), rash (35.5% vs. 3.7%), pyrexia (30.6% vs. 7.4%), cough (29.0% vs. 22.2%), asthenia (27.4% vs. 0.0%), dyspnea (25.8% vs. 18.5%), decreased weight (25.8% vs. 14.8%),</s><s>decreased appetite (24.2% vs. 11.1%),</s><s>nausea (22.6% vs. 14.8%), and anemia (21.0% vs. 3.7%).</s><s>The most frequent grade 3-4</s></p><p><s>AEs irrespective of the study drug relationship (≥5% incidence in either arm) were stomatitis (11.3% vs. 0.0%), hyperglycemia (9.7% vs. 0.0%), diarrhea (6.5% vs. 0.0%), hypophosphatemia (6.5% vs. 0.0%), dyspnea (4.8% vs. 7.4%), and hypertension (0.0% vs. 7.4%).</s></p><p><s>The most frequently reported (≥20% incidence in either arm) drug-related any grade AEs (everolimus vs. placebo) were stomatitis (53.2% vs. 18.5%), rash (35.5% vs. 3.7%), fatigue (32.3% vs. 22.2%), peripheral edema (27.4% vs. 0.0%), diarrhea (25.8% vs. 7.4%), infections (22.6% vs. 3.7%), asthenia (22.6% vs. 0.0%), anemia (21.0% vs.</s></p><p><s>3.7%), and decreased appetite (21.0% vs. 7.4%) (Table <ref type="table">3</ref>).</s><s>The drugrelated AEs associated with infections in the lung (everolimus vs. placebo) were respiratory tract infection (including lower and upper res-  with pneumonitis had stable disease as their best response per central radiology review.</s><s>The most frequent grade 3-4 drug-related AEs (≥5% incidence in either arm) were stomatitis, hyperglycemia, and infections (Table <ref type="table">3</ref>).</s></p><p><s>There were two on-treatment deaths in each arm.</s><s>In the everolimus arm, one of the two deaths was considered to be related to the primary disease and/or to disease progression, and the other was  tigator to be related to the study medication.</s><s>In the placebo arm, one death was considered to be related to the primary disease and/ or to disease progression and the other death was attributed to "dyspnea", which was suspected by the investigator to be related to the study medication.</s><s>The AEs observed in this subgroup of patients with lung NET were similar to those reported in the overall RADI-ANT-4 patient group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">| DISCUSSION</head><p><s>There is a large unmet medical need for patients with advanced lung NETs.</s><s>Currently there is no standard antitumor systemic treatment available for these malignancies.</s><s>In this exploratory analysis of the RADIANT-4 study, everolimus was associated with a clinically meaningful improvement of 5.6 months in the median PFS compared to placebo, by central review, in patients with advanced, progressive, well-differentiated, non-functional lung NET, with 50% risk-reduction in disease progression or death.</s><s>By investigator assessment, median PFS was prolonged by a clinically meaningful time period of 10.3 months in the patients treated with everolimus compared to placebo, with 77% risk-reduction in disease progression or death.</s></p><p><s>These results strongly support the results of the central review.</s></p><p><s>Based on the results obtained in the RADIANT-4 study, everolimus has been approved worldwide for the treatment of patients with advanced, progressive, well-differentiated, non-functional (GI and lung) NET. <ref type="bibr" target="#b22">22</ref></s><s>Therefore, everolimus represents the first agent ever approved for non-functioning lung NET.</s><s>At primary diagnosis, 52.2% of patients were diagnosed at stage IV; the majority of the remaining patients progressed to stage IV within a median time period of 28.8 months.</s><s>The relatively short time for progression from initial diagnosis suggests that lung NET is not an indolent disease.</s></p><p><s>Although data on different therapies for patients with lung NET have been reported from retrospective or single-arm phase II prospective trials, no published data from a phase III trial are currently available, apart from the data for everolimus. <ref type="bibr" target="#b19">19,</ref><ref type="bibr" target="#b22">22</ref> </s><s> randomized, double-blind, phase III study (SPINET, NCT02683941) evaluating the efficacy and safety of lanreotide Autogel vs placebo is ongoing in patients with well-differentiated, metastatic, and/or unresectable, typical or atypical lung carcinoids.</s><s>Eligibility of patients with lung NET according to the AC and TC definitions, as reported in the WHO classification, was not mandatory for enrollment in the RADIANT-4 study.</s><s>To  <ref type="bibr" target="#b25">25,</ref><ref type="bibr" target="#b26">26</ref> The improvement in median PFS (5.6 months) observed in patients with lung NET treated with everolimus is consistent with the improvement in median PFS (7.1 months) observed in the overall RADIANT-4 cohort.</s><s>The reduction in the risk of disease progression or death in the lung NET subgroup (50%) is similar to that seen in the total population in the RADIANT-4 study (52%).</s><s>More patients in the everolimus arm experienced tumor shrinkage in the RADI-ANT-4 cohort as well as in the lung subgroup (63.6% and 57.9% in the everolimus arm vs. 25.9% and 13.0% in the placebo arm); these results are consistent with the cytoreductive properties of everolimus.</s><s><ref type="bibr" target="#b22">22</ref> The data from our analysis supports the preliminary evidence of efficacy that was observed when everolimus was added to octreotide in patients with functional lung NET.</s><s><ref type="bibr" target="#b19">19</ref> The results from the three-arm, randomized phase II LUNA trial (n = 112), comparing pasireotide in combination with everolimus vs everolimus alone and pasireotide alone in patients with typical and atypical lung or thymic carcinoids further support the efficacy of everolimus in this setting.</s><s><ref type="bibr" target="#b27">27</ref> The LUNA study achieved the preplanned statistical objective of a 9-month PFS rate &gt;20% in all three arms.</s><s>The observed 9-month PFS rates were 39.0%, 33.3%, and 58.5% with a median PFS of 8.5, 12.5, and 11.8 months in pasireotide alone, everolimus alone, and combination arms, respectively.</s></p><p><s>The preplanned first interim OS analysis (at data cut-off date of November 28, 2014) was carried out after a total of 70 deaths and indicated that everolimus may be associated with a reduction in the risk of death (HR, 0.64; 95% CI, 0.40-1.05;</s><s>one-sided P = .037,</s><s>whereas the boundary for statistical significance was .0002). <ref type="bibr" target="#b22">22</ref></s><s>The results of a planned second interim analysis of OS (at data cut-off date of November 30, 2015), undertaken after a total of 101 deaths (53% of the total targeted 191 deaths for final OS analysis), continued to suggest a positive trend for survival benefit with everolimus, although statistical significance was not achieved. <ref type="bibr" target="#b28">28</ref></s><s>Overall survival was immature at the interim analyses.</s><s>Therefore, the OS in subgroups will be analyzed when the final OS analysis will be under- Everolimus toxicity was manageable with no new safety signals.</s></p><p><s>In patients with lung NET, drug-related pneumonitis is of special interest; however, all patients in this lung subgroup who had grade 1-3 drug-related non-infectious pneumonitis were effectively managed with dose modifications, without requiring treatment discontinuation.</s><s>The AEs were similar to those reported in the overall RADIANT-4 cohort <ref type="bibr" target="#b22">22</ref> and was consistent with the known safety profile of everolimus. <ref type="bibr" target="#b21">21</ref></s><s> conclusion, although this is an exploratory subgroup analysis of a randomized phase III trial and the study was not powered for a comparison between subgroups, it represents the largest series of lung NET patients ever included in a phase III trial.</s><s>These data indicate that treatment with everolimus can result in a clinically meaningful improvement in PFS in patients with advanced, progressive, well-differentiated, non-functional NET originating in the lung.</s><s>Based on the preliminary evidence <ref type="bibr" target="#b19">19</ref> and the clinically meaningful results from the subgroup analysis of patients with lung NET in the RADI-ANT-4 study, <ref type="bibr" target="#b22">22</ref> everolimus should be recommended for patients with advanced progressive lung NET as reported in the 2016 European Neuroendocrine Tumor Society guidelines. <ref type="bibr" target="#b8">9</ref></s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Partial response was observed in one patient in each treatment arm; no patients in either arm showed complete response.Stable disease as best response was observed in 50 patients (79.4%) in the everolimus arm and 15 patients (55.6%) in the placebo arm.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>piratory tract, bronchus, and lung infections; 9 patients [14.5%] vs. 1 patient [3.7%]) and pneumonia (3 patients [4.8%] vs. 0 [0.0%]).</s><s>Of T A B L E 1 Baseline demographics and disease characteristics of patients with advanced, progressive, well-differentiated, nonfunctional lung neuroendocrine tumors (NET) treated with everolimus or placebo Characteristics Patients with lung NET (n = 90)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>F</head><label></label><figDesc><div><p><s>I G U R E 1 Progression-free survival in patients with lung neuroendocrine tumors.</s><s>Hazard ratio (HR) values presented are based on unstratified Cox regression analysis.</s><s>A, Central radiology review.</s><s>B, Local investigator review.</s><s>CI, confidence interval F I U R E 2 Best percentage change from baseline in lung neuroendocrine tumor response.</s><s>*Change in size of target lesion contradicted by lesion response of progressive disease.</s><s>Patients for whom the best percentage change in target lesions was not available and patients for whom the best percentage change was contradicted by overall lesion = unknown were excluded from the analyses attributed to "cardiac failure", which was not suspected by the inves-</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>T A B L E 2 1 )</head><label>21</label><figDesc><div><p><s>Progression-free survival (PFS) treatment effect in patients with advanced, progressive, well-differentiated, nonfunctional lung neuroendocrine tumors treated with everolimus or placebo, based on central radiology review, grouped by prior therapies No prior therapy (n = 12) 9.7 (0.9-NE) 3.6 (1.7-NE) CI, confidence interval; NE, not evaluable; SSA, somatostatin analog.</s><s>a Includes peptide receptor radionuclide therapy.</s><s>T A B L E 3 Drug-related adverse events in the lung subgroup of of patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) treated with everolimus or placebo (≥10% incidence in either arm) Preferred term, n (%) Patients with lung NET (n = 90) arm, one patient withdrew consent.</s><s>b Includes stomatitis, aphthous stomatitis, mouth ulceration, and glossitis.</s><s>cRepresents the total number of patients with stomatitis that includes mouth and stoma-derived adverse events.d</s><s>A patient with multiple adverse events within a category is counted only once in the "Total" row.</s><s>e Includes all infections.</s><s>classify a tumor as TC or AC, the surgical primary tumor sample is usually required by the pathologist.</s><s>However, in the metastatic setting (as in the RADIANT-4 cohort), percutaneous biopsies or primary tumor endobronchial ultrasound-guided fine needle aspiration biopsies of metastatic or primary sites represented the vast majority of histological material available, making it very difficult to classify the lung NET as TC or AC.</s><s>Therefore, well-differentiated tumor morphology, possibly with a thyroid transcription factor 1-positive and caudal type homeobox 2-negative immunohistochemistry, combined with a consistent clinical picture and clinical history supported the diagnosis of lung NET in RADIANT-4 in the majority of cases.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>taken after 191 deaths have occurred in the overall RADIANT-4 cohort.</s><s>At the primary analysis (at data cut-off date of November 28, 2014), 27 OS events occurred in 90 patients with lung NET (10 in the placebo arm [n = 27] and 17 in the everolimus arm [n = 63]).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Probability of progression-free survival (%)</head><label></label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell cols="2">Censoring times</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="3">Everolimus (n/N = 42/63)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="3">Placebo (n/N = 18/27)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0</cell><cell>2</cell><cell>4</cell><cell>6</cell><cell>8</cell><cell>10</cell><cell>12</cell><cell>15</cell><cell>18</cell><cell>2</cell><cell>4</cell></row><row><cell>Everolimus</cell><cell>63</cell><cell>51</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Placebo</cell><cell>27</cell><cell>15</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Kaplan−Meier medians</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">Everolimus: 13.8 months (95% CI, 9.3-22.2)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Placebo: 3.5 months (95% CI, 1.9-5.6)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">HR: 0.23 (95% CI, 0.13-0.41)</cell><cell></cell></row></table><note><p><s>Kaplan−Meier medians Everolimus: 9.2 months (95% CI, 6.8-10.9)</s><s>Placebo: 3.6 months (95% CI, 1.9-5.1)</s><s>HR: 0.50 (95% CI, 0.28-0.88)</s></p></note></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDG MENTS</head><p><s>The authors acknowledge the patients, their families, and their caregivers, as well as all the investigators.</s><s>The RADIANT-4 study group is grateful to all the physicians who contributed to the present study, and the worldwide network of research nurses, trial coordinators, and operations staff for their contributions.</s><s>We appreciate the support of the colleagues of the RADIANT-4 Study Team who contributed to the presented data.</s><s>In addition, we thank Rajasree Solipuram, PhD, Novartis Healthcare Pvt. Ltd. for providing medical editorial assistance with this manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLI CT OF INTEREST</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nicola</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">One hundred years after &quot;carcinoid&quot;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Phan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3063" to="3072" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Clinical presentation and evaluation of neuroendocrine tumors of the lung</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Detterbeck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorac Surg Clin</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="267" to="276" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Epidemiology of neuroendocrine tumours</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Taal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Visser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="3" to="7" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumors of the lung: an update</title>
		<author>
			<persName><forename type="first">N</forename><surname>Rekhtman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1628" to="1638" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hellman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Papotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Egw</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="120" to="123" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumors of the lung</title>
		<author>
			<persName><forename type="first">D</forename><surname>Granberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Neuroendocrine Tumors: Diagnosis and Management</title>
				<editor>
			<persName><forename type="first">S</forename><surname>Yalcin</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">K</forename><surname>Oberg</surname></persName>
		</editor>
		<meeting><address><addrLine>Berlin, Heidelberg</addrLine></address></meeting>
		<imprint>
			<publisher>Springer-Verlag</publisher>
			<biblScope unit="volume">2015</biblScope>
			<biblScope unit="page" from="143" to="164" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Multidisciplinary management of advanced lung neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Filosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guerrera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="S163" to="S171" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Cancer of the Lung: small cell and other neuroendocrine tumors of the lung</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Krug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rosenzweig</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<publisher>Lippincott Williams and Wilkins</publisher>
			<biblScope unit="page" from="946" to="971" />
			<pubPlace>Alphen aan den Rijn</pubPlace>
		</imprint>
	</monogr>
	<note>Cancer Principles and Practice of Oncology</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pavel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>O'toole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Costa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="172" to="185" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Longterm survival of atypical bronchial carcinoids with liver metastases, treated with octreotide</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Filosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ruffini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oliaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Papalia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Donati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rena</forename><forename type="middle">O</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="913" to="917" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Waldherr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pless</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Maecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Haldemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mueller-Brand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="941" to="945" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Long-term results of PRRT in advanced bronchopulmonary carcinoid</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mariniello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bodei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tinelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="441" to="452" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Activity of sunitinib in patients with advanced neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kulke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Meropol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3403" to="3410" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title level="m" type="main">Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)</title>
		<author>
			<persName><forename type="first">E</forename><surname>Grande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Capdevila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Castellano</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1987" to="1993" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Hoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1316" to="1323" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Brizzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berruti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferrero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">388</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bajetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Catena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Procopio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="637" to="642" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ekeblad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Janson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2986" to="2991" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study</title>
		<author>
			<persName><forename type="first">N</forename><surname>Fazio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Granberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Grossman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="955" to="962" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lombard-Bohas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baudin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="69" to="76" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Everolimus for advanced pancreatic neuroendocrine tumors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ito</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="514" to="523" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fazio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="968" to="977" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Klimstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Modlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Coppola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Suster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pancreas</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="707" to="712" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Nomenclature and classification of neuroendocrine neoplasm of the digestive system</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rindi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Bosman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Classification of Tumours of the Digestive System</title>
				<editor>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Bosman</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">F</forename><surname>Carniero</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Hruban</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Theise</surname></persName>
		</editor>
		<imprint>
			<biblScope unit="volume">2010</biblScope>
			<biblScope unit="page" from="13" to="14" />
		</imprint>
	</monogr>
	<note>4th edn</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Hendifar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Marchevsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tuli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="425" to="436" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?</title>
		<author>
			<persName><forename type="first">Gfa</forename><surname>Pelosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cossa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Diagn Pathol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="469" to="479" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ferolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Brizzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="136" to="148" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: second interim overall survival (OS) results from the RADIANT-4 study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fazio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="174" to="181" />
			<date type="published" when="2016">2016. 2018</date>
		</imprint>
	</monogr>
	<note>Cancer Sci</note>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title/>
		<idno type="DOI">10.1111/cas.13427</idno>
		<ptr target="https://doi.org/10.1111/cas.13427" />
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
